Nadine K.
- Country
- Germany
- Department
- N/A
Research Overview
- Phase 3 Randomized Open-Label Trial of Epcoritamab Versus Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Evaluation of AZD0486 Monotherapy and Combination Therapy in Mature B-Cell Malignancies: A Phase I/II Study in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and Large B-Cell Lymphoma
- Evaluation of Safety and Preliminary Efficacy of CLDN6 CAR-T and CLDN6 RNA-LPX in CLDN6-Positive Relapsed or Refractory Advanced Solid Tumors
Data & Insights
Has run more than one trial at 5 of 113 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating B-cell lymphoma, with particular emphasis on developing innovative therapeutic approaches for patients with challenging blood cancers.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Refractory Blood Cancers
- B-Cell Malignancies
Their research explores novel immunotherapy treatments for patients with advanced hematologic conditions.
Immunotherapy Research
Focused on advancing targeted immunotherapy approaches in hematologic malignancies, particularly investigating novel antibody-based treatments.
- Bispecific Antibodies
- Targeted Therapy
- Immune System Modulation
The investigator evaluates innovative therapeutic strategies against conventional treatment methods.
Treatment Resistance
Specializes in addressing relapsed and refractory disease in lymphoma patients, developing strategies for those who have exhausted standard treatment options.
- Drug Resistance Mechanisms
- Alternative Treatment Pathways
- Comparative Therapy Assessment
Their work focuses on improving outcomes for patients with treatment-resistant conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.